This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cheung, R. T. F. Articles by Adams, H. P. Search for Related Content PubMed Articles by Cheung, R. T. F. Articles by Adams, H. P., Jr Related Collections Acute Cerebral Hemorrhage Acute Cerebral Infarction Anticoagulants Antiplatelets

(Stroke. 2000;31:2517-a.)
© 2000 American Heart Association, Inc.

Letters to the Editor

Fatal Hemorrhagic Transformation of Acute Cerebral Infarction After the Use of Abciximab

Raymond T. F. Cheung, MBBS, PhD, FRCPE

Division of Neurology

David S. W. Ho, MBBS, PhD, FRACP

Division of Cardiology, Department of Medicine, Queen Mary Hospital, Hong Kong

To the Editor:

The Abciximab in Ischemic Stroke Investigators reported the encouraging results of their randomized, double-blind, placebo-controlled, dose-escalation trial.¹ Of 74 eligible and consenting patients presenting within 24 hours of onset of their ischemic stroke, 54 patients were treated with 4 escalating doses of intravenous abciximab and 20 patients with placebo. The scheduled post-study CT brain scan detected asymptomatic parenchymal hemorrhages in 7% of abciximab-treated patients and 5% of placebo-treated patients; another 11% of abciximab-treated patients had asymptomatic parenchymal hemorrhages on unscheduled brain imaging (CT or MRI) performed on days 2 through 35. Symptomatic hemorrhagic transformation was not seen, while asymptomatic parenchymal hemorrhages were associated with a higher baseline National Institute of Health Stroke Scale (NIHSS) score. We would raise the following issue for clarification by the authors and report our limited experience of using abciximab in Chinese stroke patients.

Concomitant use of antithrombotic medications during the time period of diagnosing parenchymal hemorrhage was listed in Table 3 of the article.¹ The scheduled CT brain scan detected asymptomatic parenchymal hemorrhages in patients A, D, G, H, and I, who also received concomitant antithrombotic medications, such as systemic heparin, low-dose heparin, aspirin, and warfarin sodium. Nevertheless, the study protocol required that antiplatelet agents or anticoagulants not be administered until the results of the scheduled CT brain scan became available (as stated in the subsection on Ancillary Care within Subjects and Methods).¹ The investigators stated that they were not certain whether these agents were administered before or at the time of . . . [Full Text of this Article]

Harold P. Adams, Jr, MD

Department of Neurology, University of Iowa, Iowa City, Iowa